NewAmsterdam Pharma Company (NAMS) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.12

Estimate

-$0.44

Surprise

+71.4%

Revenue (period 2026-09-30)

$19.2M

Score today

5.6/10

Revenue source: xbrl.

NewAmsterdam Pharma Company (NAMS) reported a narrower loss than forecast — adjusted EPS of -$0.12 against the -$0.44 estimate (a 71.4% beat on a still-unprofitable quarter).

• NewAmsterdam Pharma Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-04
• NewAmsterdam Pharma Q3 EPS $(0.14) Beats $(0.51) Estimate, Sales $19.164M Beat $7.340M Estimate — benzinga, 2026-11-04
• NewAmsterdam Pharma Announces Participation in Upcoming Investor Conferences — fiscal.ai, 2026-11-03

TrendMatrix currently rates NAMS Sell at 5.6/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +71.4% surprise compares with a +9.2% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$20.93

Price target

$43.62

Stop

$19.46

Upside to target

+108.4%

Reward-to-risk

8.9:1

Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.50B

P/E (fwd)

-13.7

52-week range

$19.13–$42.20

Off 52-week high

50.4%

RSI (14)

52

Volume vs avg

1.26×

Score today

5.6/10